Abstract
Objective
To assess the value of qualitative and quantitative MRI radiomics features for noninvasive prediction of immuno-oncologic characteristics and outcomes of hepatocellular carcinoma (HCC).
Methods
This retrospective, IRB-approved study included 48 patients with HCC (M/F 35/13, mean age 60y) who underwent hepatic resection or transplant within 4 months of abdominal MRI. Qualitative imaging traits, quantitative nontexture related and texture features were assessed in index lesions on contrast-enhanced T1-weighted and diffusion-weighted images. The association of imaging features with immunoprofiling and genomics features was assessed using binary logistic regression and correlation analyses. Binary logistic regression analysis was also employed to analyse the association of radiomics, histopathologic and genomics features with radiological early recurrence of HCC at 12 months.
Results
Qualitative (r = − 0.41–0.40, p < 0.042) and quantitative (r = − 0.52–0.45, p < 0.049) radiomics features correlated with immunohistochemical cell type markers for T-cells (CD3), macrophages (CD68) and endothelial cells (CD31). Radiomics features also correlated with expression of immunotherapy targets PD-L1 at protein level (r = 0.41–0.47, p < 0.029) as well as PD1 and CTLA4 at mRNA expression level (r = − 0.48–0.47, p < 0.037). Finally, radiomics features, including tumour size, showed significant diagnostic performance for assessment of early HCC recurrence (AUC 0.76–0.80, p < 0.043), while immunoprofiling and genomic features did not (p = 0.098–0929).
Conclusions
MRI radiomics features may serve as noninvasive predictors of HCC immuno-oncological characteristics and tumour recurrence and may aid in treatment stratification of HCC patients. These results need prospective validation.
Key Points
• MRI radiomics features showed significant associations with immunophenotyping and genomics characteristics of hepatocellular carcinoma.
• Radiomics features, including tumour size, showed significant associations with early hepatocellular carcinoma recurrence after resection.
Similar content being viewed by others
Abbreviations
- ADC:
-
Apparent diffusion coefficient
- AUC:
-
Area under the curve
- CE-MRI:
-
Contrast-enhanced MRI
- CT:
-
Computed tomography
- DWI:
-
Diffusion-weighted imaging
- FDR:
-
False discovery rate
- HCC:
-
Hepatocellular carcinoma
- MICSSS:
-
Multiplexed immunohistochemical consecutive staining on single slide
- MRI:
-
Magnetic resonance imaging
- OR:
-
Odds ratio
References
Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet. https://doi.org/10.1016/S0140-6736(18)30010-2
Marrero JA, Kulik LM, Sirlin C et al (2018) Diagnosis, staging and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. https://doi.org/10.1002/hep.29913
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330
Gnjatic S, Bronte V, Brunet LR et al (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 5:44
Remark R, Merghoub T, Grabe N et al (2016) In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci Immunol 1:aaf6925
Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35–51
Khemlina G, Ikeda S, Kurzrock R (2017) The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 16:149
Clark T, Maximin S, Meier J, Pokharel S, Bhargava P (2015) Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol 44:479–486
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577
Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762
Lewis S, Hectors S, Taouli B (2020) Radiomics of hepatocellular carcinoma. Abdom Radiol (NY). https://doi.org/10.1007/s00261-019-02378-5
Hectors SJ, Wagner M, Bane O et al (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep 7:2452
Taouli B, Hoshida Y, Kakite S et al (2017) Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol 27:4472–4481
American College of Radiology (ACR) (2018) CT/MRI LI-RADS® v2018. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018
Haralick RM, Shanmungam K, Dinstein I (1973) Textural features for image classification. IEEE Trans Syst Man Cybern SMC 3:610–621
Collewet G, Strzelecki M, Mariette F (2004) Influence of MRI acquisition protocols and image intensity normalization methods on texture classification. Magn Reson Imaging 22:81–91
Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503
Tan PS, Nakagawa S, Goossens N et al (2016) Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 36:108–118
Hoshida Y, Nijman SM, Kobayashi M et al (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385–7392
Goossens N, Sun X, Hoshida Y (2015) Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepatol Oncol 2:371–379
Villanueva A, Hoshida Y, Battiston C et al (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140:1501–1512 e1502
Yamashita T, Forgues M, Wang W et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461
Di Tommaso L, Franchi G, Park YN et al (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45:725–734
Llovet JM, Chen Y, Wurmbach E et al (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131:1758–1767
Hagel M, Miduturu C, Sheets M et al (2015) First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov 5:424–437
Horwitz E, Stein I, Andreozzi M et al (2014) Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 4:730–743
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500–507
Kong LQ, Zhu XD, Xu HX et al (2013) The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One 8:e59771
Wang L, Wang FS (2019) Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int. https://doi.org/10.1007/s12072-019-09967-y
Zhou W, Zhang L, Wang K et al (2017) Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging 45:1476–1484
Zimmerman MA, Ghobrial RM, Tong MJ et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 143:182–188 discussion 188
Renzulli M, Brocchi S, Cucchetti A et al (2016) Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 279:432–442
Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L (2018) A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol 24:121–127
Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25:181–200
Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721
Traverso A, Wee L, Dekker A, Gillies R (2018) Repeatability and reproducibility of Radiomic features: a systematic review. Int J Radiat Oncol Biol Phys 102:1143–1158
Chen S, Feng S, Wei J et al (2019) Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 29:4177–4187
Feng ST, Jia Y, Liao B et al (2019) Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol 29:4648–4659
Funding
This study has received funding from the Research Seed Grant no. RSD1608 from the Radiological Society of North America, and grant U01 CA172320 from the National Cancer Institute and the International Liver Cancer Association.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Bachir Taouli.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was waived by the Institutional Review Board.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• retrospective
• observational
• performed at one institution
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 6958 kb)
Rights and permissions
About this article
Cite this article
Hectors, S.J., Lewis, S., Besa, C. et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 30, 3759–3769 (2020). https://doi.org/10.1007/s00330-020-06675-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-020-06675-2